logo
Share SHARE
FONT-SIZE Plus   Neg

Gilead Sciences HIV Drug Quad Gets FDA Panel Backing

Gilead Sciences Inc. (GILD: Quote) Friday said that its experimental drug for treating HIV, known as Quad, won the backing of an FDA advisory panel.

The Antiviral Drugs Advisory Committee voted 13 to 1 in favor of Quad to treat HIV-1 infection in treatment-naive adults. The drug, which is a four-in-one combination pill of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, is meant to be taken once daily.

While the FDA is not bound by the recommendations of the panel, its guidance is usually considered by the agency. The FDA will take a final decision on the drug by August 27, 2012. Applications for marketing approval of Quad are also pending in Australia, Canada and the European Union. Market experts believe that the drug has potential to become a blockbuster.

"The Quad is the latest example of Gilead's ongoing efforts to develop highly effective and well tolerated single tablet regimens for people living with HIV," said Andrew Cheng, Senior Vice President, HIV Therapeutics and Development Operations, Gilead Sciences.

Quad's new drug application is supported by clinical studies, which met the primary study goals of being non-inferior as compared to other HIV drugs. The Quad was well tolerated with the most common adverse events noted being nausea, diarrhea, upper respiratory track infection and headache.

Currently, Gilead's Atripla is the most-prescribed HIV treatment regimen in the US. For the first quarter of 2012, Atripla sales increased 19 percent to $887.6 million, while sales from Truvada, another HIV drug, increased 13 percent to $758.3 million.

GILD closed Friday's trading on the Nasdaq at $51.84, up $0.59 or 1.15%, on a volume of 9.6 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Adoption of self-driving cars could save up to $190 billion annually in damages and hospital bills as well as drastically reduce auto accidents in the U.S., according to a new study. The study-- "Autonomous Driving -- 10 Ways in Which Autonomous Vehicles Could Reshape Our Lives"-- conducted by McKinsey... Mercedes-Benz Vans Friday said it would invest around $500 million to create a plant in Charleston, South Carolina to explore the future growth potential in North American Van market. After many years on the outside, tech giant Apple Inc. (AAPL) will finally be added to the Dow Jones Industrial Average, S&P Dow Jones Indices announced on Friday. Apple, the maker of the iPhone and iPad, will replace telecom giant AT&T Inc. (T) in the well-known stock market index.
comments powered by Disqus
Follow RTT